keyword
MENU ▼
Read by QxMD icon Read
search

Ceftaroline in childrens

keyword
https://www.readbyqxmd.com/read/28910514/pharmacokinetics-of-single-dose-ceftaroline-fosamil-in-children-with-cystic-fibrosis
#1
Jennifer Le, John S Bradley, Sara Hingtgen, Shannon Skochko, Nanette Black, Ronald N Jones, Meerana Lim, Edmund V Capparelli
BACKGROUND: Single-dose pharmacokinetics (PK) and safety of ceftaroline fosamil with population pharmacokinetic/pharmacodynamic (PK/PD) modeling for staphylococcal pneumonia was performed in children with CF. METHODS: Subjects between 6 and 18 years old were evaluated in this phase 1, open-label, single-dose, prospective study using 10 mg/kg (up to 600 mg). Non-compartmental analysis and population-based PK analyses with Monte Carlo simulation (for doses 8-20 mg/kg every 8 h, infused over 1-4 h) were conducted...
September 14, 2017: Pediatric Pulmonology
https://www.readbyqxmd.com/read/28407067/evaluation-of-a-second-sign-process-for-antimicrobial-prior-authorization
#2
Aimee M Dassner, Jennifer E Girotto
Background.: A second-sign prospective restriction of select broad-spectrum antimicrobials was fully implemented in January 2015 as a pediatric antimicrobial stewardship program (ASP) initiative to help ensure the most appropriate empiric use of ceftaroline, cefepime, fidaxomicin, linezolid, and vancomycin (intravenous). The objective of this evaluation is to assess the effectiveness of a forced second-sign process in the electronic medical record as a pediatric ASP strategy. We anticipated that the second-sign process for antibiotics would increase the appropriateness of empiric antibiotic use, as defined by preapproved criteria, clinical pathways, national guidelines, and pediatric-specific infectious diseases reference texts, while not causing significant delay in the initial administration of antibiotic therapy...
April 12, 2017: Journal of the Pediatric Infectious Diseases Society
https://www.readbyqxmd.com/read/28382572/current-clinical-trials-on-the-use-of-ceftaroline-in-the-pediatric-population
#3
REVIEW
Adam Corey, Tsz-Yin So
The rate of antibiotic resistance in children continues to rise requiring the use of new antibiotics. Ceftaroline fosamil, a newer-generation cephalosporin, was recently approved for the treatment of acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia in children aged >2 months. Ceftaroline provides coverage against staphylococcal and streptococcal infections, including methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae...
April 5, 2017: Clinical Drug Investigation
https://www.readbyqxmd.com/read/28039666/use-of-ceftaroline-fosamil-in-children-review-of-current-knowledge-and-its-application
#4
REVIEW
Juwon Yim, Leah M Molloy, Jason G Newland
Ceftaroline is a novel cephalosporin recently approved in children for treatment of acute bacterial skin and soft tissue infections and community-acquired bacterial pneumonia (CABP) caused by methicillin-resistant Staphylococcus aureus, Streptococcus pneumoniae and other susceptible bacteria. With a favorable tolerability profile and efficacy proven in pediatric patients and excellent in vitro activity against resistant Gram-positive and Gram-negative bacteria, ceftaroline may serve as a therapeutic option for polymicrobial infections, CABP caused by penicillin- and ceftriaxone-resistant S...
March 2017: Infectious Diseases and Therapy
https://www.readbyqxmd.com/read/27766567/ceftaroline-fosamil-a-review-in-complicated-skin-and-soft-tissue-infections-and-community-acquired-pneumonia
#5
REVIEW
Lesley J Scott
Intravenous ceftaroline fosamil (Zinforo™), a prodrug that is rapidly converted to its active metabolite ceftaroline, is approved for use in adults and children (from 2 months of age) with complicated skin and soft tissue infections (cSSTIs) or community-acquired pneumonia (CAP). In several multinational trials, ceftaroline fosamil was an effective and generally well tolerated treatment in adult and paediatric patients with cSSTIs or CAP. In the phase 3 CANVAS trials, ceftaroline fosamil treatment was noninferior to vancomycin plus aztreonam in adults with cSSTIs...
November 2016: Drugs
https://www.readbyqxmd.com/read/27510635/population-pk-modeling-and-target-attainment-simulations-to-support-dosing-of-ceftaroline-fosamil-in-pediatric-patients-with-acute-bacterial-skin-and-skin-structure-infections-and-community-acquired-bacterial-pneumonia
#6
Todd A Riccobene, Tatiana Khariton, William Knebel, Shampa Das, James Li, Alena Jandourek, Timothy J Carrothers, John S Bradley
Ceftaroline, the active form of the prodrug ceftaroline fosamil, is approved for use in adults with community-acquired bacterial pneumonia (CABP) or acute bacterial skin and skin structure infections (ABSSSI) in the United States and for similar indications in Europe. Pharmacokinetic (PK) data from 5 pediatric (birth to <18 years) studies of ceftaroline fosamil were combined with PK data from adults to update a population PK model for ceftaroline and ceftaroline fosamil. This model, based on a data set including 305 children, was used to conduct simulations to estimate ceftaroline exposures and percentage of time that free drug concentrations were above the minimum inhibitory concentration (%fT>MIC) for pediatric dose regimens...
March 2017: Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/27093162/a-randomized-prospective-study-of-pediatric-patients-with-community-acquired-pneumonia-treated-with-ceftaroline-versus-ceftriaxone
#7
RANDOMIZED CONTROLLED TRIAL
Christopher R Cannavino, Agnes Nemeth, Bartosz Korczowski, John S Bradley, Tanya O'Neal, Alena Jandourek, H David Friedland, Sheldon L Kaplan
BACKGROUND: Community-acquired bacterial pneumonia (CABP) remains a major infection among children, despite the use of pneumococcal vaccination. Ceftaroline fosamil is a broad-spectrum cephalosporin antibiotic with activity against many bacteria, including Streptococcus pneumoniae (both penicillin-nonsusceptible and multidrug-resistant strains) and Staphylococcus aureus (including methicillin-resistant S. aureus). This article describes the safety, tolerability, and effectiveness of ceftaroline fosamil in the treatment of pediatric patients hospitalized with CABP, from a randomized, active-controlled, observer-blinded clinical study (registration number NCT01530763)...
July 2016: Pediatric Infectious Disease Journal
https://www.readbyqxmd.com/read/26168680/-antibiotic-resistance-and-serotype-pattern-of-streptococcus-pneumoniae-isolated-from-children-in-st-petersburg-in-2010-2013
#8
O S Kalinogorskaya, S S Belanov, M O Volkova, V V Gostev, S V Sidorenko
The surveillance of the serotype pattern and antibiotic resistance of S. pneumoniae in various geographical regions is required for the validity of rational etiotrophic therapy of pneumococcal infections and the choice of the optimal vaccines for their prophylaxis. 250 S. pneumoniae isolates from children with acute otitis or pneumonia and healthy carriers in St. Petersburg in 2010-2013 were investigated. The analysis of the serotype pattern of the pneumococci showed that 13-valent conjugate vaccine was the most active (86...
2015: Antibiotiki i Khimioterapii︠a︡, Antibiotics and Chemoterapy [sic]
https://www.readbyqxmd.com/read/24716805/pharmacokinetics-and-safety-of-recently-approved-drugs-used-to-treat-methicillin-resistant-staphylococcus-aureus-infections-in-infants-children-and-adults
#9
REVIEW
Martyn Gostelow, Daniel Gonzalez, P Brian Smith, Michael Cohen-Wolkowiez
Methicillin-resistant Staphylococcus aureus (MRSA) remains a significant cause of morbidity in hospitalized infants. Over the past 15 years, several drugs have been approved for the treatment of S. aureus infections in adults (linezolid, quinupristin/dalfopristin, daptomycin, telavancin, tigecycline and ceftaroline). The use of the majority of these drugs has extended into the treatment of MRSA infections in infants, frequently with minimal safety or dosing information. Only linezolid is approved for use in infants, and pharmacokinetic data in infants are limited to linezolid and daptomycin...
May 2014: Expert Review of Clinical Pharmacology
https://www.readbyqxmd.com/read/24702974/-pharmacokinetics-and-pharmacodynamics-of-ceftaroline
#10
REVIEW
Santiago Grau, Luisa Sorlí, Sonia Luque
Ceftaroline is administered intravenously in the form of a prodrug, ceftaroline fosamil, which is rapidly hydrolyzed by plasma phosphatases to its active form, ceftaroline. In general, the pharmacokinetics of ceftaroline differ little from those of other cephalosporins. A proportional increase in both the peak plasma concentration (Cmax) and the area under the curve (AUC) have been observed when the drug is administered in increasing doses, which demonstrates its linear pharmacokinetics. Half the dose of ceftaroline is excreted actively through the kidneys...
March 2014: Enfermedades Infecciosas y Microbiología Clínica
https://www.readbyqxmd.com/read/24138510/combination-therapy-the-propitious-rationale-for-drug-development
#11
REVIEW
Neetu Phougat, Savita Khatri, Anu Singh, Mrridula Dangi, Manish Kumar, Rajesh Dabur, Anil Kumar Chhillar
Therapeutic options for many infections are extremely limited and at crisis point. We run the risk of entering a second pre-antibiotic era. There had been no miracle drug for the patients infected by resistant microbial pathogens. Most of the very few new drugs under development have problems with their toxicity, or pharmacokinetics and pharmacodynamics. We are already decades behind in the discovery, characterization and development of new antimicrobials. In that scenario, we could not imagine surviving without newer and effective antimicrobial agents...
January 2014: Combinatorial Chemistry & High Throughput Screening
https://www.readbyqxmd.com/read/22357801/activity-of-ceftaroline-against-serotyped-streptococcus-pneumoniae-isolates-from-europe-and-south-africa-associated-with-community-acquired-bacterial-pneumonia-2007-08
#12
COMPARATIVE STUDY
Ian Morrissey, Anne Leakey
OBJECTIVES: To determine the activity of ceftaroline (the active metabolite of the prodrug ceftaroline fosamil), a new cephalosporin recently approved in the USA for the treatment of community-acquired bacterial pneumonia, against serotyped Streptococcus pneumoniae causing community-acquired bacterial pneumonia from Europe and South Africa. METHODS: During 2007-08, 74 centres submitted 857 isolates of S. pneumoniae from patients with community-acquired bacterial pneumonia...
June 2012: Journal of Antimicrobial Chemotherapy
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"